Novolog, Novorapid(insulin aspart)
Fiasp, NovoMix, NovoRapid, Novolog, Ryzodeg (insulin aspart) is a protein pharmaceutical. Insulin aspart was first approved as Novorapid on 1999-09-07. It has been approved in Europe to treat diabetes mellitus.
Download report
Favorite
Commercial
Trade Name
FDA
EMA
Fiasp, Novolog
CombinationsNovolog mix (discontinued: Ryzodeg)
Drug Products
FDA
EMA
Reference product - 351(a)
Reference product - 351(a)
Interchangeable product - 351(k)
Interchangeable product - 351(k)
Biosimilar product - 351(k)
Biosimilar product - 351(k)
Insulin aspart
Insulin aspart
+
Insulin aspart protamine
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Novolog Mix 70/30 | insulin aspart protamine and insulin aspart | Novo Nordisk Inc. | N-21172 RX | 2001-11-01 | 2 products |
Show 2 discontinued
Insulin aspart
+
Insulin degludec
Tradename | Proper name | Company | Number | Date | Products |
---|---|---|---|---|---|
Ryzodeg 70/30 | insulin degludec and insulin aspart | Novo Nordisk Inc. | N-203313 DISCN | 2015-09-25 | 1 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
---|---|---|
fiasp | Biologic Licensing Application | 2019-12-19 |
novolog mix 70/30 | Biologic Licensing Application | 2023-02-04 |
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
A: Alimentary tract and metabolism drugs
— A10: Drugs used in diabetes
— A10A: Insulins and analogues
— A10AB: Insulins and analogues for injection, fast-acting
— A10AB05: Insulin aspart
— A10AD: Insulins and analogues for injection used in diabetes, intermediate- or long-acting combined with fast-acting
— A10AD05: Insulin aspart
— A10AD06: Insulin degludec and insulin aspart
HCPCS
No data
Clinical
Clinical Trials
452 clinical trials
View more details
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/trials-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 14 | 8 | 61 | 70 | 58 | 210 |
Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 57 | 10 | 50 | 34 | 48 | 196 |
Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 2 | 2 | 6 | 2 | 6 | 17 |
Hyperglycemia | D006943 | HP_0003074 | R73.9 | — | — | — | 4 | 3 | 7 |
Hypoglycemia | D007003 | HP_0001943 | E16.2 | — | 1 | 1 | 2 | — | 3 |
Gestational diabetes | D016640 | HP_0009800 | O24.4 | — | — | 1 | 1 | — | 2 |
Hyperkalemia | D006947 | HP_0002153 | E87.5 | — | — | — | 1 | — | 1 |
Coronary artery disease | D003324 | I25.1 | — | — | — | 1 | — | 1 | |
Atherosclerosis | D050197 | EFO_0003914 | I25.1 | — | — | — | 1 | — | 1 |
Arteriosclerosis | D001161 | EFO_0009086 | I70 | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Cystic fibrosis | D003550 | EFO_0000390 | E84 | — | 1 | 1 | — | 1 | 2 |
Pregnancy complications | D011248 | — | — | 1 | — | — | 1 | ||
Diabetes complications | D048909 | — | 1 | 1 | — | — | 1 | ||
Asthma | D001249 | EFO_0000270 | J45 | — | — | 1 | — | — | 1 |
Leukemia | D007938 | C95 | — | — | 1 | — | — | 1 | |
Lymphoma | D008223 | C85.9 | — | — | 1 | — | — | 1 | |
Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | — | — | 1 | — | — | 1 |
Diabetic neuropathies | D003929 | EFO_1000783 | — | 1 | 1 | — | — | 1 | |
Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | — | — | 1 |
Pharmacokinetics | D010599 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Alzheimer disease | D000544 | EFO_0000249 | F03 | 2 | 1 | — | — | — | 2 |
Cognitive dysfunction | D060825 | G31.84 | 1 | 1 | — | — | — | 2 | |
Exercise | D015444 | EFO_0000483 | — | 1 | — | — | — | 1 | |
Delirium | D003693 | R41.0 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Healthy volunteers/patients | — | 22 | — | — | — | — | 22 | ||
Diabetic retinopathy | D003930 | EFO_0003770 | 1 | — | — | — | — | 1 | |
Olfaction disorders | D000857 | R43.0 | 1 | — | — | — | — | 1 | |
Taste disorders | D013651 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Glucose intolerance | D018149 | HP_0000833 | R73.03 | — | — | — | — | 2 | 2 |
Congenital hyperinsulinism | D044903 | — | — | — | — | 1 | 1 | ||
Diabetic ketoacidosis | D016883 | EFO_1000897 | — | — | — | — | 1 | 1 | |
Chronic renal insufficiency | D051436 | N18 | — | — | — | — | 1 | 1 | |
Latent autoimmune diabetes in adults | D000071698 | — | — | — | — | 1 | 1 | ||
Infections | D007239 | EFO_0000544 | — | — | — | — | 1 | 1 | |
Insulin resistance | D007333 | EFO_0002614 | — | — | — | — | 1 | 1 | |
Fetal macrosomia | D005320 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common name | INSULIN ASPART |
INN | insulin aspart |
Description | Insulin aspart |
Classification | Protein |
Drug class | — |
Image (chem structure or protein) | |
Structure (InChI/SMILES or Protein Sequence) | — |
Identifiers
PDB | — |
CAS-ID | 116094-23-6 |
RxCUI | 51428 |
ChEMBL ID | CHEMBL1201496 |
ChEBI ID | — |
PubChem CID | — |
DrugBank | DB01306 |
UNII ID | D933668QVX (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
Novorapid - Novo Nordisk
$
€
£
₣
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Ryzodeg - Novo Nordisk
$
€
£
₣
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Novomix - Novo Nordisk
$
€
£
₣
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Fiasp - Novo Nordisk
$
€
£
₣
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/sales-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-terms-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 3,983 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
![](https://www.pharmakb.com/hubfs/raw_assets/public/ccd-theme/images/generated-html-images/top-adverse-reactions-plot.png)
Mock data
Subscribe for the real data
Subscribe for the real data
1,374 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more